-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceuticals.
com Pharmaceutical Stock Market] Shortly after the start of 2022, Asieris Pharmaceuticals, a new stock listed on the Sci-Tech Innovation Board, broke the first day of its listing, and today, another new pharmaceutical stock listed on the Sci-tech Innovation Board broke out
.
On January 18, Maiwei Bio was listed on the Science and Technology Innovation Board, and it broke at the opening, fell 8.
05%, and reported 32 yuan per share
.
It is worth mentioning that this is a young pharmaceutical company that has only been established for 4 years, but it currently has 15 varieties under development, of which 2 new drugs independently developed are in the queue for listing
.
According to the data, Maiwei Bio was founded in Zhangjiang, Shanghai in 2017.
Relying on the rich resources and experience accumulated by the founding team in the field of biomedicine, especially in the field of macromolecules, the company has built a whole industry chain system from early discovery to production and sales.
The product pipeline is rich, and the competitiveness and global layout have begun to show results
.
According to the prospectus, Maiwei Bio’s R&D pipeline includes 15 antibody or fusion protein drugs, of which 11 are innovative drugs and 3 are biosimilars, covering autoimmunity, tumor, metabolism, infection, ophthalmology and other therapeutic areas
.
There are 3 varieties that have submitted marketing applications, 1 of which will be approved for marketing in the first quarter of 2022; 3 varieties are in key clinical registration; 6 varieties are in other clinical stages (including implied licenses); 3 varieties
.
From the perspective of the potential competitiveness of the products, among the 15 products under development, 2 are currently the first drugs with the same target of domestic companies to enter the clinic, namely 9MW1911 and 9MW2821; 2 are potential global first- In-class drugs are 9MW3011 and 6MW3411 respectively; 4 products are currently advanced in China, including 9MW0321, 9MW0311, 8MW2311 and 9MW1411; in addition, 3 products have been authorized at home and abroad, namely 8MW0511 and 8MW0511 and 9MW3311
.
From the perspective of product pipeline, it is not only rich, but also has certain differences
.
Among these varieties, 9MW1111 is an innovative drug with mature targets, and 9MW3311, 9MW1411, 9MW1911, 6MW3211 and 9MW2821 are innovative drugs that are rapidly followed up by popular targets
.
Among them, 9MW2821 is the first domestic Nectin-4 ADC new drug.
Preclinical studies have shown that 9MW2821 has stronger anti-tumor activity and better safety than the foreign benchmark drug Padcev
.
The global ADC drug market is huge and is expected to reach US$16.
4 billion by 2026, of which the new Nectin-4 ADC drug Padceve is expected to reach US$3.
5 billion, with huge market potential
.
If 9MW2821 is successfully listed, it may compete for this market
.
6MW3211 is the first dual-antibody new drug developed by Maiwei Bio
.
The product has been shown to have a certain level of safety
.
At present, there are three PD-L1/CD47 double antibodies developed by Innovent Bio, Shenghe Bio, and Shangjian Bio in China, and 6MW3211 is expected to become the fourth one in China
.
It is understood that since its establishment, Maiwei Bio has followed the model of making source innovation and realizing business demands through commercial transformation, aiming to become a biopharmaceutical company with advantages of the whole industry chain
.
The company's research and development has long focused on tumors, especially tumor immunotherapy-related and age-related aspects.
In the field of tumors, it is expected that through the comprehensive regulation of the tumor microenvironment, the comprehensive role of a variety of innate immune cells will be exerted, thereby further improving the efficacy of tumor immunotherapy.
In addition, with the development of China's economy and the continuous improvement of living standards, people are paying more and more attention to chronic diseases, including inflammation, metabolism, ophthalmology and other fields related to the natural aging of the human body
.
com Pharmaceutical Stock Market] Shortly after the start of 2022, Asieris Pharmaceuticals, a new stock listed on the Sci-Tech Innovation Board, broke the first day of its listing, and today, another new pharmaceutical stock listed on the Sci-tech Innovation Board broke out
.
On January 18, Maiwei Bio was listed on the Science and Technology Innovation Board, and it broke at the opening, fell 8.
05%, and reported 32 yuan per share
.
It is worth mentioning that this is a young pharmaceutical company that has only been established for 4 years, but it currently has 15 varieties under development, of which 2 new drugs independently developed are in the queue for listing
.
According to the data, Maiwei Bio was founded in Zhangjiang, Shanghai in 2017.
Relying on the rich resources and experience accumulated by the founding team in the field of biomedicine, especially in the field of macromolecules, the company has built a whole industry chain system from early discovery to production and sales.
The product pipeline is rich, and the competitiveness and global layout have begun to show results
.
According to the prospectus, Maiwei Bio’s R&D pipeline includes 15 antibody or fusion protein drugs, of which 11 are innovative drugs and 3 are biosimilars, covering autoimmunity, tumor, metabolism, infection, ophthalmology and other therapeutic areas
.
There are 3 varieties that have submitted marketing applications, 1 of which will be approved for marketing in the first quarter of 2022; 3 varieties are in key clinical registration; 6 varieties are in other clinical stages (including implied licenses); 3 varieties
.
From the perspective of the potential competitiveness of the products, among the 15 products under development, 2 are currently the first drugs with the same target of domestic companies to enter the clinic, namely 9MW1911 and 9MW2821; 2 are potential global first- In-class drugs are 9MW3011 and 6MW3411 respectively; 4 products are currently advanced in China, including 9MW0321, 9MW0311, 8MW2311 and 9MW1411; in addition, 3 products have been authorized at home and abroad, namely 8MW0511 and 8MW0511 and 9MW3311
.
From the perspective of product pipeline, it is not only rich, but also has certain differences
.
Among these varieties, 9MW1111 is an innovative drug with mature targets, and 9MW3311, 9MW1411, 9MW1911, 6MW3211 and 9MW2821 are innovative drugs that are rapidly followed up by popular targets
.
Among them, 9MW2821 is the first domestic Nectin-4 ADC new drug.
Preclinical studies have shown that 9MW2821 has stronger anti-tumor activity and better safety than the foreign benchmark drug Padcev
.
The global ADC drug market is huge and is expected to reach US$16.
4 billion by 2026, of which the new Nectin-4 ADC drug Padceve is expected to reach US$3.
5 billion, with huge market potential
.
If 9MW2821 is successfully listed, it may compete for this market
.
6MW3211 is the first dual-antibody new drug developed by Maiwei Bio
.
The product has been shown to have a certain level of safety
.
At present, there are three PD-L1/CD47 double antibodies developed by Innovent Bio, Shenghe Bio, and Shangjian Bio in China, and 6MW3211 is expected to become the fourth one in China
.
It is understood that since its establishment, Maiwei Bio has followed the model of making source innovation and realizing business demands through commercial transformation, aiming to become a biopharmaceutical company with advantages of the whole industry chain
.
The company's research and development has long focused on tumors, especially tumor immunotherapy-related and age-related aspects.
In the field of tumors, it is expected that through the comprehensive regulation of the tumor microenvironment, the comprehensive role of a variety of innate immune cells will be exerted, thereby further improving the efficacy of tumor immunotherapy.
In addition, with the development of China's economy and the continuous improvement of living standards, people are paying more and more attention to chronic diseases, including inflammation, metabolism, ophthalmology and other fields related to the natural aging of the human body
.
